Sequent Scientific Ltd

Sequent Scientific Ltd

₹ 122 2.13%
22 Apr 12:51 p.m.
About

Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries.

Key Points

Business segment & Revenue Mix FY22
The company has 2 business segments: Formulation and API. [1]

  • Market Cap 3,044 Cr.
  • Current Price 122
  • High / Low 156 / 70.2
  • Stock P/E
  • Book Value 25.3
  • Dividend Yield 0.00 %
  • ROCE -3.43 %
  • ROE -8.98 %
  • Face Value 2.00

Pros

Cons

  • Stock is trading at 4.88 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 10.9% over past five years.
  • Company has a low return on equity of 3.68% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
355 362 321 351 358 384 341 338 375 367 333 346 329
291 319 300 331 322 350 339 335 365 370 341 331 307
Operating Profit 65 43 20 20 36 33 2 3 10 -3 -8 15 22
OPM % 18% 12% 6% 6% 10% 9% 1% 1% 3% -1% -2% 4% 7%
3 2 3 1 4 4 -2 1 3 -60 -23 10 7
Interest 6 3 3 3 3 6 7 8 10 11 10 13 13
Depreciation 12 13 13 13 13 13 14 13 14 15 14 15 15
Profit before tax 50 29 7 4 24 18 -21 -18 -10 -89 -56 -3 1
Tax % 23% 19% 63% -251% 21% 45% 27% 75% 4% -4% 38% -123% -617%
38 24 3 14 19 10 -15 -4 -10 -92 -35 -7 11
EPS in Rs 1.43 0.83 0.04 0.58 0.69 0.36 -0.60 -0.15 -0.36 -3.75 -1.40 -0.34 0.33
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
346 327 395 443 606 684 848 1,039 1,179 1,362 1,413 1,421 1,375
309 340 389 425 550 641 765 914 1,009 1,150 1,303 1,409 1,349
Operating Profit 37 -13 6 18 56 43 83 125 170 212 109 12 26
OPM % 11% -4% 2% 4% 9% 6% 10% 12% 14% 16% 8% 1% 2%
10 3 -54 48 14 9 436 9 10 -0 11 -58 -66
Interest 30 33 34 43 38 28 33 33 36 24 16 36 47
Depreciation 23 29 29 32 46 40 41 42 51 51 52 56 60
Profit before tax -5 -73 -110 -8 -14 -17 444 59 94 137 53 -138 -146
Tax % 73% 11% -1% -40% -19% 3% 3% 3% 13% 24% 15% 11%
-1 -65 -110 -12 -16 -16 431 57 82 104 45 -122 -123
EPS in Rs -0.13 -5.39 -8.09 -0.70 -0.78 -0.57 17.30 1.97 2.81 3.84 1.65 -4.86 -5.16
Dividend Payout % 0% 0% 0% 0% 0% 0% 1% 10% 0% 13% 0% 0%
Compounded Sales Growth
10 Years: 16%
5 Years: 11%
3 Years: 6%
TTM: -4%
Compounded Profit Growth
10 Years: 0%
5 Years: %
3 Years: %
TTM: -111%
Stock Price CAGR
10 Years: 9%
5 Years: 10%
3 Years: -23%
1 Year: 58%
Return on Equity
10 Years: 9%
5 Years: 6%
3 Years: 4%
Last Year: -9%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 21 23 27 30 48 49 49 49 50 50 50 50 50
Reserves 101 60 19 32 885 928 599 657 637 678 642 649 582
269 311 418 473 312 416 305 325 343 277 365 444 461
156 192 159 372 278 503 380 346 424 381 378 374 408
Total Liabilities 547 586 623 908 1,523 1,896 1,332 1,378 1,454 1,386 1,435 1,517 1,501
230 227 238 474 586 684 476 498 577 536 564 605 592
CWIP 64 89 43 39 24 33 18 23 13 31 12 55 35
Investments 0 2 0 59 428 428 239 180 171 83 38 0 1
253 268 342 336 485 751 599 677 693 737 821 856 872
Total Assets 547 586 623 908 1,523 1,896 1,332 1,378 1,454 1,386 1,435 1,517 1,501

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
21 -4 -45 -24 -0 -7 45 116 115 115 31 17
-65 -55 -81 -157 -310 -116 7 -68 -72 10 -94 -65
62 35 146 179 309 147 -57 -20 -43 -139 67 32
Net Cash Flow 18 -24 20 -1 -2 24 -5 28 0 -14 4 -16

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 74 73 77 95 116 136 111 98 99 93 85 88
Inventory Days 130 173 175 153 164 165 125 134 132 139 160 152
Days Payable 236 306 198 147 175 208 127 141 133 119 119 107
Cash Conversion Cycle -32 -59 54 101 105 93 110 92 98 112 126 132
Working Capital Days -34 5 47 57 99 79 86 77 74 88 106 115
ROCE % 5% -10% -4% 9% 2% 1% 40% 9% 12% 16% 6% -3%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
53.86% 53.52% 53.02% 53.02% 52.79% 52.79% 52.79% 52.79% 52.79% 52.79% 52.79% 52.79%
13.60% 14.12% 6.42% 5.84% 6.45% 6.57% 6.25% 5.89% 6.27% 6.03% 6.12% 6.16%
2.49% 2.03% 2.13% 2.04% 2.27% 2.79% 2.81% 2.92% 2.92% 3.23% 7.23% 7.59%
29.46% 29.73% 37.89% 38.60% 38.10% 37.48% 37.76% 38.00% 37.64% 37.57% 33.69% 33.29%
0.60% 0.60% 0.54% 0.51% 0.39% 0.39% 0.39% 0.39% 0.39% 0.39% 0.17% 0.17%
No. of Shareholders 86,8481,24,0141,67,8121,91,0921,97,1761,93,9541,96,2311,91,8751,87,4741,84,5211,72,8531,66,593

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls